Shearman & Sterling represented Ultragenyx Pharmaceutical in purchasing 600,000 additional shares of common stock of Arcturus Therapeutics at $16.00 per share consistent with the Equity Purchase…
Ultragenyx Pharmaceutical’s Acquisition Of Shares in Arcturus Therapeutics
![](https://globallegalchronicle.com/wp-content/uploads/2020/06/Robert_Masella.jpg)